High-rolling investors have positioned themselves bearish on TG Therapeutics TGTX, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TGTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for TG Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 62% bearish. Among all the options we identified, there was one put, amounting to $36,500, and 7 calls, totaling $279,550.
Latest Startup Investment Opportunities:
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $30.0 for TG Therapeutics during the past quarter.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in TG Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to TG Therapeutics's substantial trades, within a strike price spectrum from $15.0 to $30.0 over the preceding 30 days.
TG Therapeutics 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| TGTX | CALL | SWEEP | BULLISH | 08/16/24 | $30.00 | $88.4K | 32 | 260 |
| TGTX | CALL | TRADE | BULLISH | 02/23/24 | $21.50 | $44.0K | 0 | 200 |
| TGTX | PUT | SWEEP | BEARISH | 01/19/24 | $18.00 | $36.5K | 247 | 400 |
| TGTX | CALL | TRADE | BULLISH | 01/19/24 | $18.00 | $36.0K | 2.0K | 177 |
| TGTX | CALL | SWEEP | BEARISH | 01/12/24 | $19.50 | $32.0K | 11 | 25 |
About TG Therapeutics
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Following our analysis of the options activities associated with TG Therapeutics, we pivot to a closer look at the company's own performance.
Present Market Standing of TG Therapeutics
- With a volume of 3,536,963, the price of TGTX is down -2.39% at $17.59.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 53 days.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest TG Therapeutics options trades with real-time alerts from Benzinga Pro.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
